Abbott Reportedly Buys Russia's NPO Petrovax Drug Firm For $280 Million
This article was originally published in PharmAsia News
Executive Summary
Abbott Laboratories reportedly has agreed to acquire Russia's NPO Petrovax Pharm, a developer and producer of vaccines and drugs aimed at immunology.